SHERIDAN, WYOMING – November 9, 2024 – Alcon, a global leader in eye care dedicated to helping people see brilliantly, presented its latest innovations and clinical data at the American Academy of Ophthalmology (AAO) 2024 annual meeting. The company showcased advancements in glaucoma therapy, retina surgery, and dry eye treatment, demonstrating its commitment to improving patient outcomes and streamlining surgical workflows.
Voyager™ DSLT: Revolutionizing Glaucoma Treatment
Alcon's latest innovation for glaucoma therapy, the Voyager™ Direct Selective Laser Trabeculoplasty (DSLT) device, was a highlight of the event. This groundbreaking technology offers a first-line treatment option for glaucoma patients, eliminating the need for a gonio lens or manual aiming required for traditional Selective Laser Trabeculoplasty (SLT).
Voyager™ DSLT's proprietary eye-tracking technology ensures accurate, automated treatment delivery through the limbus. This patient- and physician-friendly design, combined with its precision treatment and streamlined workflow, positions Voyager™ DSLT as a game-changer in glaucoma care.
UNIFEYE™ and UNIPEXY™: Advancing Retina Surgery
Alcon also introduced two new handheld gas delivery systems for retina surgeons: UNIFEYE™ and UNIPEXY™. UNIFEYE™ integrates all components for gas delivery into one convenient device, ensuring a predictable and precise gas-to-air ratio. This eliminates the risk of delivering an unintended gas-to-air mixture and simplifies the setup process, saving time and gas.
UNIPEXY™ is a highly portable system designed for in-clinic convenience. It features an integrated single-dose pico-cylinder containing perfluoropropane (C3F8) or sulfur hexafluoride (SF6), providing surgeons with everything they need for pneumatic retinopexy in a single handheld device.
Both UNIFEYE™ and UNIPEXY™ will be commercially available in 2025.
AR-15512: A Promising Solution for Dry Eye
Alcon presented new pivotal data for AR-15512 (acoltremon ophthalmic solution 0.003%), an investigational drug candidate for treating the signs and symptoms of dry eye disease. The Phase 3 pivotal study results were presented in an electronic poster titled "AR-15512: A Novel TRPM8 Agonist for the Treatment of the Signs and Symptoms of Dry Eye."
Commitment to Efficiency and Performance
"The heart of Alcon remains a relentless pursuit of improving outcomes and helping patients see brilliantly," said Jim Di Filippo, Vice President and General Manager of U.S. Surgical at Alcon. "Our vision extends beyond this; we are equally focused on efficiency, ensuring our innovations deliver quality and performance. From pioneering technologies like Voyager™ DSLT and UNIFEYE™ to our cloud-connected Alcon Vision Suite, we are dedicated to advancing ophthalmology and streamlining surgical workflows."
About Alcon
Alcon is a global leader in eye care with a heritage spanning over 75 years. The company offers a broad portfolio of products to enhance sight and improve people's lives, including surgical and vision care products for conditions like cataracts, glaucoma, retinal diseases, and refractive errors. Alcon's products serve people in over 140 countries.